Matthew Perry’s Stepmom Asks Court to Give ‘Heartless Woman’ Jasveen Sangha the Maximum Prison Sentence

Why It Matters

The statement highlights growing legal scrutiny of illicit ketamine networks and may set a precedent for harsher penalties in high‑profile drug‑related deaths, influencing both criminal justice and drug policy.

Key Takeaways

• Step‑mother submitted victim impact statement urging maximum sentence
• Sangha pleaded guilty in 2025 after lengthy investigation
• Five defendants charged in connection with Perry’s ketamine death
• Case underscores risks of unregulated ketamine distribution

Pulse Analysis

Matthew Perry’s tragic death in 2023 reignited conversations about the perils of ketamine misuse, especially among high‑profile individuals. The actor, who openly battled addiction, succumbed to acute ketamine toxicity in his Pacific Palisades home, prompting a federal investigation that uncovered a clandestine supply chain. Law enforcement identified five suspects, including two physicians, a personal assistant, and Jasveen Sangha, who allegedly orchestrated the distribution network. Their arrests in 2024 and subsequent guilty pleas have placed the case at the intersection of celebrity culture and drug enforcement, drawing media scrutiny and public empathy.

The sentencing phase now centers on Sangha, dubbed the “Ketamine Queen,” whose victim impact statement from Perry’s stepmother demanded the harshest possible punishment. Sangha’s guilty plea, secured in September 2025 after a protracted investigation, reflects the prosecution’s strategy to hold key distributors accountable. While three co‑defendants accepted plea deals earlier, Sangha’s later admission underscores the complexities of negotiating with individuals who wield significant influence over illicit drug markets. The court’s decision will weigh factors such as the scale of distribution, the fatal outcome, and the emotional testimony of grieving family members, potentially shaping sentencing guidelines for similar cases.

Beyond the courtroom, the case spotlights broader regulatory challenges surrounding ketamine, a substance increasingly used off‑label for mental‑health treatment yet vulnerable to diversion. Policymakers are now grappling with balancing legitimate medical access against the risk of abuse, especially as the drug’s popularity rises. High‑profile incidents like Perry’s death may accelerate calls for stricter monitoring, tighter prescribing controls, and enhanced penalties for illegal distribution. For industry stakeholders, the outcome could influence compliance protocols, risk‑management strategies, and public perception of ketamine’s safety profile.